Acomplia
Trovati 9 articoli
- Acomplia: suspension of marketing authorisation as risks outweigh benefits
- European Medicines Agency ( EMEA ) has completed a review of Rimonabant ( Acomplia ) after concerns about its psychiatric safety. Thereview has found that the benefits of Rimonabant do not outweigh the risks of psychiatric reactions in clinical use. The marketing authorisation for this medicine w... (Leggi Articolo)
- EMEA: Acomplia must not be used in patients on antidepressants or with major depression
- The EMEA ( European Medicines Agency ) has recommended contraindicating Acomplia ( Rimonabant ), in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects. Doctors in the EU ( European Union ) have already been ... (Leggi Articolo)
- Acomplia: safety issues
- Rimonabant ( Acomplia / Zimulti ) is a cannabinoid receptor antagonist. It acts by blocking a specific type of receptor called cannabinoid type 1 ( CB1 ) receptors. These receptors are found in the nervous system and are part of the system that the body uses to control food intake. By blocking th... (Leggi Articolo)
- Obesity and overweight: modest weight loss with Acomplia, Meridia and Xenical
- Patients taking anti-obesity drugs will only see modest weight loss and many will remain significantly obese or overweight. The study, which looked at the long-term effectiveness of anti-obesity medications, found that three drugs recommended for long-term use – Orlistat ( Xenical ), Sibutrami... (Leggi Articolo)
- Acomplia is associated with severe adverse psychiatric events
- Patients given Rimonabant are at increased risk of severe psychiatric events. The prevalence of obesity continues to increase worldwide, and there is a demand for effective and safe anti-obesity agents that can produce and maintain weight loss and thereby reduce prevalence of conditions associ... (Leggi Articolo)
- Rimonabant, a obesity drug: loss of a few kilos, many questions
- Acomplia ( Rimonabant ), a CB1 cannabinoid receptor antagonist, was approved by EMEA ( European Medicines Agency ) for the adjuvant treatment of obesity, in combination with a low-calorie diet and physical exercise. Rimonabant is used together with diet and exercise to treat adult patients: ... (Leggi Articolo)
- Acomplia shows modest benefit in reducing body weight
- Use of the weight-loss medication Rimonabant ( Acomplia ) produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels. Approximately two-thirds of U.S. adults are overweight or obese, which greatly increases the risk of developing diabetes mell... (Leggi Articolo)
- Appetite-related circuits: integration of endocannabinoid and leptin signaling regulates the excitability of neurons
- Marijuana, or more specifically its active ingredient, tetrahydrocannabinol, has a well-documented tendency to stimulate hunger. And while researchers have traced this property to cannabinoid receptors in the brain, they have had little understanding of the neural circuitry underlying this effe... (Leggi Articolo)
- Acomplia lowers blood glucose, reduces weight, waist size, and modifies lipids in diabetes mellitus type 2
- Rimonabant ( Acomplia ) has demonstrated that it can lower blood glucose and reduce weight and waist circumference, as well as modify lipids associated with diabetic dyslipidemia, in patients with type 2 diabetes. Results of the RIO-Diabetes ( Rimonabant In Obesity ) study show impressive find... (Leggi Articolo)
